Teva Stock Surges After Celiac Disease Drug Meets Phase 2a Trial Goals

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) surged in pre-market trading after the company reported positive results from a Phase 2a clinical study of its investigational drug for celiac disease. The stock climbed 3.3% ahead of the market open on the news that the antibody, TEV ’408, met its primary goal.

Trial Meets Primary Endpoint

Teva announced that its anti-interleukin-15 antibody demonstrated a statistically significant and clinically meaningful benefit for patients. The trial's key findings, according to the company, include:

• The study met its primary endpoint, showing significant prevention of gluten-induced intestinal damage at week 8 compared to a placebo.
• The drug exhibited a favorable tolerability profile with no new safety signals emerging during the trial.

To discuss the data, Teva held a dedicated investor call, amplifying market focus on the clinical development.

Strategic and Market Impact

Ad

The positive outcome holds strategic importance for Teva's drug pipeline, as TEV ’408 is being positioned as a potential multi-indication treatment for autoimmune conditions. The molecule is already advancing into a Phase 2b study for vitiligo, another autoimmune disorder.

Teva is developing the drug in partnership with Royalty Pharma, which has committed up to $500 million to fund its clinical development. The stock's rise was a company-specific event, outperforming a broadly neutral market and standing out against pharmaceutical peers who did not report similar catalysts.

Context of Teva's Turnaround

This successful trial adds to a series of positive developments reinforcing Teva's ongoing transformation narrative. In recent months, the company has also secured an investment-grade credit upgrade from Moody's, received FDA priority review for its Tourette syndrome treatment ecopipam, and raised its full-year revenue guidance. The latest pipeline news pushes the stock toward its 52-week high.